Novel immunotherapy combinations for genitourinary cancers
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial Carcinoma /von 2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2020-01-24 / Cancer Immunol. Immunother. 2020 Mar;69(3):477-488Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update
/in Dendritic Cells, International Publications /von 2020-01-23 / Pharmaceutics 2020 Jan;12(2)Breast cancer stem cell RNA-pulsed dendritic cells enhance tumor cell killing by effector T cells
/in Breast Cancer, Dendritic Cells, International Publications /von 2020-01-23 / Oncol Lett 2020 Mar;19(3):2422-2430Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors
/in Dendritic Cells, Glioblastoma, International Publications /von 2020-01-16 / NPJ Vaccines 2020;5:5Combination Therapy with Vitamin C Could Eradicate Cancer Stem Cells
/in International Publications, Micronutrients /von 2020-01-03 / 2020 01;10(1)Efficacy of Combination Neoadjuvant Chemotherapy and Regional Inductive Moderate Hyperthermia in the Treatment of Patients With Locally Advanced Breast Cancer
/in Breast Cancer, Hyperthermia, International Publications /von 2020-01-01 / Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820963599A Narrative Review of Regional Hyperthermia: Updates From 2010 to 2019
/in Hyperthermia, International Publications /von 2020-01-01 / Integr Cancer Ther 2020 Jan-Dec;19:1534735420932648Heating technology for malignant tumors: a review
/in Hyperthermia, International Publications /von 2020-01-01 / Int J Hyperthermia 2020;37(1):711-741
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution